- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04017546
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
January 24, 2024 updated by: Cyclacel Pharmaceuticals, Inc.
A Phase I Combination Study of CYC065 and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
Study Overview
Detailed Description
This is an open-label, single arm, dose escalation study in patients with relapsed or refractory AML or MDS.
Treatment will be administered on an outpatient basis and all patients will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in combination with venetoclax.
One treatment cycle is 4 weeks.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Previously treated AML or MDS based on WHO classification and having at least 10% blasts in peripheral blood
- ECOG 0-2
- Adequate renal function
- Adequate liver function
- INR <=1.2 in patients not receiving chronic anticoagulation
- At least 2 weeks from prior cytotoxic chemotherapy, radiation therapy, major surgery or other investigational cancer therapy
- Agree to practice effective contraception
Exclusion Criteria:
- AML is of the subtype of APL or extramedullary myeloid tumor without bone marrow involvment
- Known AML involvement in CNS that is symptomatic and active
- Currently receiving radiotherapy, biological therapy, or any other investigational agents
- Uncontrolled intercurrent illness
- Pregnant or lactating
- Known to be HIV-positive
- Known active hepatitis B and/or hepatitis C infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CYC065 and venetoclax
CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15.
Venetoclax will be taken daily on Day 1 through Day 15.
One cycle will be 28 days or 4 weeks.
|
intravenous infusion
oral capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD)
Time Frame: At the end of cycle 1 (each cycle is 28 days)
|
Number of patients who experience dose-limiting toxicity (DLT)
|
At the end of cycle 1 (each cycle is 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic effect
Time Frame: At the end of cycle 1 (each cycle is 28 days)
|
plasma drug level
|
At the end of cycle 1 (each cycle is 28 days)
|
Pharmacodynamic effect
Time Frame: At the end of cycle 1 (each cycle is 28 days)
|
MCL-1 level in peripheral white blood cells
|
At the end of cycle 1 (each cycle is 28 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-tumor activity
Time Frame: from the date of first dose of CYC065 to 4 weeks after the last dose of CYC065
|
Number of patients achieving complete remission, partial remission, hematological improvement as evaluated using International Working Group (IWG) response criteria
|
from the date of first dose of CYC065 to 4 weeks after the last dose of CYC065
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Gautam Borthakur, MD, M.D. Anderson Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 2, 2019
Primary Completion (Actual)
November 15, 2022
Study Completion (Actual)
April 5, 2023
Study Registration Dates
First Submitted
July 8, 2019
First Submitted That Met QC Criteria
July 11, 2019
First Posted (Actual)
July 12, 2019
Study Record Updates
Last Update Posted (Estimated)
January 25, 2024
Last Update Submitted That Met QC Criteria
January 24, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CYC065-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
Eilean TherapeuticsRecruiting
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
-
Glycostem Therapeutics BVRecruiting
-
Etan OrgelAstellas Pharma Global Development, Inc.No longer available
-
Chinese PLA General HospitalNavy General Hospital, BeijingCompleted
-
University Hospital Inselspital, BerneWithdrawn
Clinical Trials on CYC065
-
Cyclacel Pharmaceuticals, Inc.Active, not recruiting
-
Cyclacel Pharmaceuticals, Inc.RecruitingLymphoma | Solid Tumor, AdultUnited States, Korea, Republic of, Spain
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
Cyclacel Pharmaceuticals, Inc.Completed
-
Cyclacel Pharmaceuticals, Inc.CompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisNational Cancer Institute, FranceRecruitingPediatric CancerItaly, France, Denmark, Germany, Netherlands, Spain, United Kingdom